Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/244—Interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2066—IL-10
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/5428—IL-10

Definitions

• This invention relates to the use of antagonists against IL-10 for pharmaceutical administration to patients infected with a immunodeficiency virus.
• the administration of these antagonists restores the ability of T helper cells to produce IL-2.
• This invention provides methods of increasing the level of IL-2 produced by T helper cells in a patient infected with a human immunodeficiency virus.
• the method comprises administering an amount of an antagonist of interleukin 10 wherein said amount is effective to increase the patient's T helper cell production of IL-2.
• the antagonists are preferably administered intravenously.
• a preferred antagonist is an antibody specific for binding to IL-10.
• the antibodies can be chimeric, recombinant, polyclonal or monoclonal. Autologous antibodies, human or humanized antibodies are preferred for safety when human patients are being treated.
• the preferred single dosage of antibodies is 1-10 mg/kg body weight per antibody. Alternatively the amount of the antibody administered in a single dose is about 10 to about 100 ⁇ g per milliliter of patient sera.
• This invention provides an effective means for increasing production of IL-2 in T helper cells when said levels are being inhibited by excessive levels of IL-10 attendant an infection of lentiviruses known as the human immunodeficiency virus [HIV].
• HIV human immunodeficiency virus
• This chronic and often fatal viral infection is typified by an imbalance in T helper cellular responses.
• the result of this imbalance is an inhibition of IL-2 production by nonvirally infected T helper cells due to excessive levels of IL-10.
• the IL-10 is produced by a number of different cells including a subset of the T helper cells.
• IL-2 is responsible for T cell proliferation and is a key indicator of the status of the immune system.
• Antagonists of IL-10 can be made by mutating the amino acid sequence of IL-10 using standard mutagenesis methods. Such methods include the use of M13 vectors to introduce single site mutations, to delete random amino acids from IL-10 or to add amino acids. The resulting muteins are then tested in standard assays for the ability to compete with nonmutated IL-10. Suitable assays are described below and include in vitro cell assays where IL-2 dependent proliferation is initiated by the presence of exogenous IL-10. This strategy have been used to characterize the functional domains of numerous proteins such as thrombomodulin, human growth factor and tissue plasminogen activator.
• the antagonist can be an antibody specific for binding to IL-10 [ ⁇ IL-10] and which interferes with its binding to the T- helper receptor, ⁇ IL-10 is produced in a variety of conventional ways.
• a general review of antibody production can be found in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Pubs., N.Y. (1988) or in Colligan et al. Eds., 1991 and Suppl. Current Protocols in Immunology, Green Wiley, NY, NY.
• Antibodies can be a polyclonal mixture or monoclonal.
• Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources. Antibodies also include the immunore active portions of intact immunoglobulins.
• ⁇ IL-10 antibodies involve administering an amount of antigen sufficient to induce a humoral response in a mammal.
• the antibodies are either collected from the mammal's sera or lymphocytes removed, immortalized and those cell clones secreting the desired antibodies isolated and cultured for harvest of the desired antibodies.
• Antibodies against IL-10 are described by Mosmann et al, 1990 /. Immunol. 145:2938.
• the antigens can either be intact IL-10 or immunoreactive peptides.
• Recombinant expression of IL-10 is a convenient means for obtaining IL-10 for use as antigens.
• Specific techniques for expressing and purifying IL-10 are known. Expression of IL-10 is described in PCT/US/03554 (WO/91 /00349) and in Malefyt, et al., 1992, Curr. Opin. Immunology, 4:314-320.
• peptide synthesis may be used to obtain intact or immunoreactive portions of IL-10.
• the antibodies for use in this invention are preferably autologous for the patient thereby minimizing further immunological problems. Immunodefi ⁇ ent individuals will tend to be less reactive to non-self antibodies, and thus non-self antibodies derived from cells of the same species are also useful. Antibodies of different species are useful but means to control possible adverse immi oreactions must be undertaken. For example, humanized rat antibodies can minimize immune responses in human patients.
• the antibodies for use in this invention are typically neutralizing antibodies and will preferably have binding constants which are greater than or approximates the affinity of IL-10 for its natural receptor. Antibodies having a binding constant 100-fold less than these cytokines for their corresponding receptors are less preferred. Binding comparisons are carried out using standard equilibrium methods. The basic technology is described in Chapter 25 of Vol. 1: Immunochemistry, Ed. D.M. Weir, 4th Ed. 1986, Blackwell Scientific Publ. 25. 1-25.30. Alternatively, one can use an assay for determining the molar excess of antibody which neutralizes a defined amount of IL-10 in a standard in vitro bioassay. Examples of such assays are found in Mosmann and Fong, 1989, /. Immunol.
• the means of adinudistration of the antagonists are typically parenteral, preferably intravenous.
• the antagonists are infused into the patient using standard intravenous techniques.
• the antagonists are first suspended into a sterile, physiologically-compatible media, such as phosphate buffered saline.
• Pharmaceutically acceptable excipients such as lecithin, glucose, dextrose, antibiotics may also be included with the antagonists.
• the antagonists are antibodies, they are administered in an amount which provides circulating levels of ⁇ IL-10 at about 1 to 150 ⁇ g/ml and preferably 10 to 100 ⁇ g/ml of sera for each antibody.
• the antibodies have a 2-7 day half -life and repeated administration is necessary when levels of ⁇ IL-10 are below these levels.
• Total amount of ⁇ IL-10 applied per administration are between 1 and 10 mg/kg of body weight for each antibody.
• the method will increase IL-2 production and it is preferred that said levels approach or exceed 100% of normal. Increases of greater than 50% of the IL-2 production before treatment are considered good. Treatment can be terminated when the T helper cells are producing levels of IL-2 at 10 to 100% of normal when measured by any number of conventional assays.
• the first category are bioassays that measure IL-2 dependent proliferation of any of several immortal cell lines which proliferate in the presence of IL-2.
• An example of such a cell line is CTLL.
• Cell division is measured by radiolabelled thymidine uptake.
• the second category are functional assays and involve the use of immunoassays directly measuring IL-2 such as ELISA.
• ELISA immunoassays directly measuring IL-2

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Microbiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Virology (AREA)
• Mycology (AREA)
• Toxicology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pyrrole Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25485948

Family Applications (1)

Country Status (6)

Cited By (4)

Citations (2)

• 1993
  • 1993-09-16 EP EP93921492A patent/EP0667789A1/en not_active Withdrawn
  • 1993-09-16 JP JP6508193A patent/JPH08501549A/ja active Pending
  • 1993-09-16 WO PCT/US1993/008562 patent/WO1994006473A1/en not_active Application Discontinuation
  • 1993-09-16 AU AU48567/93A patent/AU4856793A/en not_active Abandoned
  • 1993-09-16 CA CA002144648A patent/CA2144648A1/en not_active Abandoned
  • 1993-09-17 MX MX9305713A patent/MX9305713A/es unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events